Skip to main content
TNXP
NASDAQ Life Sciences

Tonix Pharmaceuticals第四季度亏损每股3.98美元

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$13.296
Mkt Cap
$171.488M
52W Low
$12.8
52W High
$69.97
Market data snapshot near publication time

summarizeSummary

Tonix Pharmaceuticals报告第四季度每股亏损3.98美元。该财务更新为投资者提供了新的数据点，继公司最近获得转移到Nasdaq Global Select Market的批准以及其纤维肌痛药物的阳性后验Phase 3数据之后。尽管临床和市场上市新闻是积极的，但巨大的季度亏损引发了人们对公司现金流耗尽和财务跑道的担忧，特别是对于处于开发阶段的制药公司。交易者将密切关注未来的财务报表，以寻找运营效率改善或计划资本增发以支持其产品管道的迹象。

在该公告发布时，TNXP的交易价格为$13.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.7亿。 52周交易区间为$12.80至$69.97。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed TNXP - Latest Insights

TNXP
Apr 29, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharma Advances Lyme Disease Candidate TNX-4800 to Planned Phase 2, Reports Positive Phase 1 Data
Sentiment: Positive
View Wiseek Article
TNXP
Apr 23, 2026, 7:11 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharmaceuticals Reports Encouraging Preclinical Immuno-Oncology Data at AACR Meeting
Sentiment: Positive
View Wiseek Article
TNXP
Mar 31, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Tonix Pharmaceuticals Announces Positive Phase 1 Data for Lyme Disease Candidate TNX-4800, Outlines Phase 2 Study
Sentiment: Positive
View Wiseek Article
TNXP
Mar 30, 2026, 8:00 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Shareholders to Vote on Critical Reverse Stock Split and Dilutive Incentive Plan Amidst Delisting Concerns
Sentiment: Negative
View Wiseek Article
TNXP
Mar 26, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharma Doses First Patient in Phase 1 Migraine Study for TNX-1900
Sentiment: Positive
View Wiseek Article
TNXP
Mar 20, 2026, 5:12 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Shareholders to Vote on Reverse Stock Split and Evergreen Dilutive Stock Plan Amidst Going Concern Warning
Sentiment: Negative
View Wiseek Article
TNXP
Mar 18, 2026, 5:03 PM EDT
Filing Type: 4
Importance Score:
7
CEO Seth Lederman Buys $223K in Shares Following Going Concern Warning
Sentiment: Positive
View Wiseek Article
TNXP
Mar 12, 2026, 5:30 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Tonix Pharmaceuticals' Q4 Loss Hits $3.98 Per Share
Sentiment: Negative
View Wiseek Article
TNXP
Mar 12, 2026, 5:29 PM EDT
Filing Type: 10-K
Importance Score:
9
Auditor Raises Substantial Doubt on Tonix Pharma's Going Concern Amidst Deep Losses and Short Cash Runway
Sentiment: Negative
View Wiseek Article
TNXP
Mar 10, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Tonix Pharmaceuticals Presents Strong Post-Hoc Phase 3 Data for FDA-Approved Fibromyalgia Drug TONMYA™
Sentiment: Positive
View Wiseek Article